Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Fertility can be successfully preserved in breast cancer patients, shows study

The first long-term record of how cancer patients made use of their stored eggs and embryos after cancer treatment is presented today at the 36th Annual Meeting of ESHRE.

6 Jul 2020

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

1 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Research shows how a protein's small change leads to big trouble for cells

In molecular biology, chaperones are a class of proteins that help regulate how other proteins fold. Folding is an important step in the manufacturing process for proteins. When they don't fold the way they're supposed to, it can lead to the development of diseases such as cancer.

30 Jun 2020

Engineered immune cells attack solid-tumor cancer cells from humans and mice

A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

30 Jun 2020

Survey: Most American women have not heard of breast implant-related lymphoma

Only about 1 out 7 American women have heard about breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) - an immune system cancer occurring in a small percentage of women with breast implants, according to a new survey.

25 Jun 2020

A metabolic enzyme drives B cell lymphomas and could be a potential drug target

Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target.

24 Jun 2020

Common cancer treatments do not worsen COVID-19 infection, study finds

The characterization of COVID-19 in patients with cancer remains limited in published studies and nationwide surveillance analyses.

24 Jun 2020

Producing CAR T cell therapy at a lower cost

Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system.

23 Jun 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020

Beta adrenergic agonists can help decrease risk of graft vs. host disease in alloBMT recipients

New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center's Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease during allogeneic blood/marrow transplant - a potentially curative treatment for selected patients with hematologic disorders - can be decreased using an existing class of drugs called beta adrenergic agonists.

12 Jun 2020

Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress

Gilead Sciences, Inc. and Kite, a Gilead Company, are pleased to support the Virtual Edition of the 25th European Hematology Association Annual Congress, taking place 11–21 June 2020.

From Gilead Sciences, Inc. 10 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.

3 Jun 2020

New drug can prevent life-threatening anaphylaxis, shows study

For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause.

3 Jun 2020

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.

2 Jun 2020

Developing an international consortium to improve clinical decision-making in Hodgkin lymphoma

A harmonization of 'big data' in examining long-term outcomes with contemporary treatment for pediatric and adult Hodgkin lymphoma patients is yielding a new approach to inform future clinical trial design and enhance clinical decision-making.

30 May 2020

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

30 May 2020

Lymphoma News and Research

Further Reading

Fertility can be successfully preserved in breast cancer patients, shows study

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Research shows how a protein's small change leads to big trouble for cells

Engineered immune cells attack solid-tumor cancer cells from humans and mice

Survey: Most American women have not heard of breast implant-related lymphoma

A metabolic enzyme drives B cell lymphomas and could be a potential drug target

Common cancer treatments do not worsen COVID-19 infection, study finds

Producing CAR T cell therapy at a lower cost

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

Beta adrenergic agonists can help decrease risk of graft vs. host disease in alloBMT recipients

Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

New drug can prevent life-threatening anaphylaxis, shows study

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Developing an international consortium to improve clinical decision-making in Hodgkin lymphoma

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

Researchers test new treatment protocol for lymphoma

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Researchers find a 'skinny' gene

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News